TAVNEOS

This brand name is authorized in Austria, Estonia, Spain, France, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Poland

Active ingredients

The drug TAVNEOS contains one active pharmaceutical ingredient (API):

1 Avacopan UNII O880NM097T - AVACOPAN

Avacopan is a selective antagonist of the human complement 5a receptor (C5aR1 or CD88) and competitively inhibits the interaction between C5aR1 and the anaphylatoxin C5a. The specific and selective blockade of C5aR1 by avacopan reduces the pro-inflammatory effects of C5a, which include neutrophil activation, migration, and adherence to sites of small blood vessel inflammation, vascular endothelial cell retraction and permeability. Read about Avacopan

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
TAVNEOS Hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L04AJ05		L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AJ Complement inhibitors
Discover more medicines within L04AJ05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1877261, 1877272
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1211605002
Country: FR	Base de données publique des médicaments	Identifier(s): 69292539
Country: IL	מִשְׂרַד הַבְּרִיאוּת	Identifier(s): 9254
Country: IT	Agenzia del Farmaco	Identifier(s): 049881016, 049881028
Country: JP	医薬品医療機器総合機構	Identifier(s): 3999056M1026
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1093994, 1093995, 1096003
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100465431
Country: US	FDA, National Drug Code	Identifier(s): 73556-168